Clinical Trial

An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label long-term safety and efficacy study of orally administered SAT-3247 in patients with DMD that previously participated in SAT-3247-CL-101. The study will assess the long-term safety, tolerability and potential efficacy of long-term dosing of 60 mg of orally administered SAT-3247 in a 5-days on/2-days off (i.e. weekday dosing) regimen in an open-label design through 11 months- for a total of 12 months of treatment including the duration of the SAT-3247-CL-101 study. The study will enroll up to 10 participants that previously participated in the SAT-3247-CL-101 study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-04; most recent amendment 2026-04-20.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-09-03
Trial Details
NCT Number NCT06867107
Lead Sponsor Satellos Bioscience, Inc.
Conditions Duchenne Muscular Dystrophy (DMD)
Enrollment 10 participants
Start Date 2025-08-20
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-23